Medical encounters for TUD diagnosis in patients with T2DM and TUD (with obesity)
(Comparision between matched semaglutide vs other anti–diabetes medications cohorts)

Size/cohort	Exposure	Comparison	cases (overall risk) (Exposure)	cases (overall risk) (Comparison)	RD (95% CI)		HR (95% CI)
4,649	semaglutide	insulins	927 (19.9%)	1,110 (23.9%)	−3.9% (−5.6%, −2.3%)		0.74 (0.67–0.80)
4,652	semaglutide	metformin	931 (20.0%)	1,086 (23.3%)	−3.3% (−5.0%, −1.7%)		0.83 (0.76–0.91)
3,514	semaglutide	DPP–4i	662 (18.8%)	831 (23.6%)	−4.8% (−6.7%, −2.9%)		0.75 (0.67–0.83)
3,617	semaglutide	SGLT2i	712 (19.7%)	826 (22.8%)	−3.2% (−5.0%, −1.3%)		0.82 (0.74–0.90)
4,056	semaglutide	SU	789 (19.5%)	942 (23.2%)	−3.8% (−5.6%, −2.0%)		0.79 (0.72–0.87)
1,609	semaglutide	TZD	279 (17.3%)	325 (20.2%)	−2.9% (−5.6%, −0.2%)		0.81 (0.69–0.95)
4,018	semaglutide	other GLP–1RAs	787 (19.6%)	879 (21.9%)	−2.3% (−4.1%, −0.5%)		0.87 (0.79–0.96)

0.30 0.40   0.60 0.80 1.0   2.0   3.00

Hazard Ratio (HR)